Keywordsanti-beta 2 glycoprotein 1 antibodies; beta 2 glycoprotein 1; platelet; antiphospholipid antibody; antiphospholipid syndrome; systemic lupus erythematosus; antiphospholipid syndrome; anticardiolipin antibodies; low/medium antibody threshold; chemiluminescent immunoassay; antiphospholipid antibodies; natural antibodies; innate immunity; B1 B cells; antiphospholipid syndrome; antiphospholipid antibody; beta-2 glycoprotein I; isotypes; domain specific antibodies; autoimmunity; antiphospholipid antibodies; end stage kidney disease; early graft loss; thrombosis antiphospholipid syndrome; aPL; B2GPI; IgA; antiphospholipid antibodies; lupus anticoagulant; anticardiolipin antibodies; cancer; malignancies; catastrophic antiphospholipid syndrome; activated partial thromboplastin time; antiphospholipid antibodies; antiphospholipid syndrome; dilute prothrombin time; dilute Russell’s viper venom time; lupus anticoagulant; mixing tests; Taipan snake venom time; neutrophil extracellular traps; NETosis; autophagy; antibodies; antiphospholipid syndrome; beta2-glycoprotein I; antiphospholipid syndrome; antiphospholipid antibodies; anticardiolipin antibody; antiphospholipid antibodies; anti-cardiolipin antibodies; anti-β2 glycoprotein I antibodies; complement; platelet; systemic lupus erythematosus; cell-bound complement activation products (CB-CAPs)
